Trial Profile
An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DECADE
- 23 Sep 2022 Results evaluating albuminuria lowering effect of drug presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 14 Dec 2017 New trial record